Rani Therapeutics Holdings, Inc. Class A Share Price
RANIRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $0.86 | Prev. Close $0.87 | Circuit Range N/A |
Day Range $0.86 - $0.90 | Year Range $0.39 - $3.85 | Volume 9,937 |
Average Traded $0.89 |
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $0.85 | $0.89 | +0.00% |
30-Apr-26 | $0.85 | $0.89 | +2.31% |
29-Apr-26 | $0.85 | $0.86 | +0.35% |
28-Apr-26 | $0.86 | $0.86 | -2.93% |
27-Apr-26 | $0.97 | $0.89 | -4.93% |
24-Apr-26 | $0.92 | $0.93 | +2.98% |
23-Apr-26 | $0.92 | $0.91 | -4.12% |